Technical analysis of Adaptimmune Therapeutics plc (ADAP): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +0.00% |
| 1 year | -33.29% |
| 3 years | -92.72% |
| 5 years | -99.00% |
52-Week Range
| 52-week High | $0.86 |
| 52-week Low | $0.02 |
| Avg Volume (90d) | 82.5M |
Technical Indicators
| SMA 50 | $0.10 |
| SMA 200 | $0.28 |
| Beta | 2.49 |
| 30-day Volatility (annualised) | 465.4% |
| Price vs SMA 50 | -47.7% |
| Price vs SMA 200 | -80.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $0.05 |
| Market Cap | $75M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | -0.18 |
| EV / EBITDA | -1.42 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.69 |
| Current Ratio | 1.52 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -5.47 |